Yiru Fang

List of Publications by Year
in descending order

171 papers	8,190 citations	109321 35 h-index	58581 82 g-index
173 all docs	173 docs citations	173 times ranked	17945 citing authors

#	Article	IF	Citations
1	Clinical and immunological features of severe and moderate coronavirus disease 2019. Journal of Clinical Investigation, 2020, 130, 2620-2629.	8.2	3,820
2	Reduced default mode network functional connectivity in patients with recurrent major depressive disorder. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9078-9083.	7.1	441
3	The Risk and Prevention of Novel Coronavirus Pneumonia Infections Among Inpatients in Psychiatric Hospitals. Neuroscience Bulletin, 2020, 36, 299-302.	2.9	178
4	Major Depressive Disorder: Advances in Neuroscience Research and Translational Applications. Neuroscience Bulletin, 2021, 37, 863-880.	2.9	107
5	Disrupted intrinsic functional brain topology in patients with major depressive disorder. Molecular Psychiatry, 2021, 26, 7363-7371.	7.9	82
6	Altered resting-state dynamic functional brain networks in major depressive disorder: Findings from the REST-meta-MDD consortium. NeuroImage: Clinical, 2020, 26, 102163.	2.7	76
7	Alterations of microRNA-124 expression in peripheral blood mononuclear cells in pre- and post-treatment patients with major depressive disorder. Journal of Psychiatric Research, 2016, 78, 65-71.	3.1	74
8	A study of N-methyl-D-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression. Psychopharmacology, 2014, 231, 685-693.	3.1	65
9	Dissociated large-scale functional connectivity networks of the precuneus in medication-naïve first-episode depression. Psychiatry Research - Neuroimaging, 2015, 232, 250-256.	1.8	65
10	Validating GWAS-Identified Risk Loci for Alzheimer's Disease in Han Chinese Populations. Molecular Neurobiology, 2016, 53, 379-390.	4.0	62
11	Ratio of mBDNF to proBDNF for Differential Diagnosis of Major Depressive Disorder and Bipolar Depression. Molecular Neurobiology, 2017, 54, 5573-5582.	4.0	62
12	Surface Vulnerability of Cerebral Cortex to Major Depressive Disorder. PLoS ONE, 2015, 10, e0120704.	2.5	62
13	Plasma levels of Th17-related cytokines and complement C3 correlated with aggressive behavior in patients with schizophrenia. Psychiatry Research, 2016, 246, 700-706.	3.3	59
14	Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: A report of OPERATION study. Journal of Affective Disorders, 2013, 150, 834-839.	4.1	58
15	Venlafaxine inhibits the upregulation of plasma tumor necrosis factor-alpha (TNF-α) in the Chinese patients with major depressive disorder: A prospective longitudinal study. Psychoneuroendocrinology, 2013, 38, 107-114.	2.7	58
16	Alterations in effective connectivity anchored on the insula in major depressive disorder. European Neuropsychopharmacology, 2014, 24, 1784-1792.	0.7	58
17	Elevated serum levels of FGF-2, NGF and IGF-1 in patients with manic episode of bipolar disorder. Psychiatry Research, 2014, 218, 54-60.	3.3	58
18	CFH Variants Affect Structural and Functional Brain Changes and Genetic Risk of Alzheimer's Disease. Neuropsychopharmacology, 2016, 41, 1034-1045.	5.4	58

#	Article	IF	Citations
19	Altered brain network modules induce helplessness in major depressive disorder. Journal of Affective Disorders, 2014, 168, 21-29.	4.1	57
20	The role of BDNF, NTRK2 gene and their interaction in development of treatment-resistant depression: Data from multicenter, prospective, longitudinal clinic practice. Journal of Psychiatric Research, 2013, 47, 8-14.	3.1	56
21	<i>Complement C7</i> is a novel risk gene for Alzheimer's disease in Han Chinese. National Science Review, 2019, 6, 257-274.	9.5	55
22	Brain-derived neurotrophic factor levels and bipolar disorder in patients in their first depressive episode: 3-year prospective longitudinal study. British Journal of Psychiatry, 2014, 205, 29-35.	2.8	54
23	Comorbidity of depressive and anxiety disorders: challenges in diagnosis and assessment. Shanghai Archives of Psychiatry, 2014, 26, 227-31.	0.7	53
24	Identification of plasma biomarkers for distinguishing bipolar depression from major depressive disorder by iTRAQ-coupled LC–MS/MS and bioinformatics analysis. Psychoneuroendocrinology, 2017, 86, 17-24.	2.7	51
25	Biotypes of major depressive disorder: Neuroimaging evidence from resting-state default mode network patterns. NeuroImage: Clinical, 2020, 28, 102514.	2.7	51
26	IL-23 and TGF-β1 levels as potential predictive biomarkers in treatment of bipolar I disorder with acute manic episode. Journal of Affective Disorders, 2015, 174, 361-366.	4.1	50
27	Mitochondrial DNA haplogroup B5 confers genetic susceptibility to Alzheimer's disease in Han Chinese. Neurobiology of Aging, 2015, 36, 1604.e7-1604.e16.	3.1	50
28	The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease. International Journal of Geriatric Psychiatry, 2014, 29, 713-719.	2.7	49
29	Comparisons of the Efficacy and Tolerability of Extended-Release Venlafaxine, Mirtazapine, and Paroxetine in Treatment-Resistant Depression. Journal of Clinical Psychopharmacology, 2010, 30, 357-364.	1.4	48
30	A Pilot Study of the Efficacy and Safety of Paroxetine Augmented With Risperidone, Valproate, Buspirone, Trazodone, or Thyroid Hormone in Adult Chinese Patients With Treatment-Resistant Major Depression. Journal of Clinical Psychopharmacology, 2011, 31, 638-642.	1.4	47
31	Different levels of pro- and anti-inflammatory cytokines in patients with unipolar and bipolar depression. Journal of Affective Disorders, 2018, 237, 65-72.	4.1	47
32	Female-specific effect of the BDNF gene on Alzheimer's disease. Neurobiology of Aging, 2017, 53, 192.e11-192.e19.	3.1	46
33	Potential contribution of increased soluble IL-2R to lymphopenia in COVID-19 patients. Cellular and Molecular Immunology, 2020, 17, 878-880.	10.5	45
34	Association of DNA methylation in BDNF with escitalopram treatment response in depressed Chinese Han patients. European Journal of Clinical Pharmacology, 2018, 74, 1011-1020.	1.9	42
35	Sociodemographic and clinical features of bipolar disorder patients misdiagnosed with major depressive disorder in <scp>C</scp>hina. Bipolar Disorders, 2013, 15, 199-205.	1.9	41
36	Neurotrophic Tyrosine Kinase Receptor Type 2 (NTRK2) Gene Associated with Treatment Response to Mood Stabilizers in Patients with Bipolar I Disorder. Journal of Molecular Neuroscience, 2013, 50, 305-310.	2.3	40

#	Article	IF	Citations
37	Prevalence, risk factors and clinical characteristics of suicidal ideation in Chinese patients with depression. Journal of Affective Disorders, 2018, 235, 135-141.	4.1	40
38	Decreased serum fibroblast growth factor - 2 levels in pre- and post-treatment patients with major depressive disorder. Neuroscience Letters, 2014, 579, 168-172.	2.1	39
39	HTR1A/1B DNA methylation may predict escitalopram treatment response in depressed Chinese Han patients. Journal of Affective Disorders, 2018, 228, 222-228.	4.1	38
40	Somatic symptoms vary in major depressive disorder in China. Comprehensive Psychiatry, 2018, 87, 32-37.	3.1	37
41	MiRNA-206 and BDNF genes interacted in bipolar I disorder. Journal of Affective Disorders, 2014, 162, 116-119.	4.1	35
42	Identification of IL6 as a susceptibility gene for major depressive disorder. Scientific Reports, 2016, 6, 31264.	3.3	35
43	Novel Risk Loci Associated With Genetic Risk for Bipolar Disorder Among Han Chinese Individuals. JAMA Psychiatry, 2021, 78, 320.	11.0	35
44	The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. Signal Transduction and Targeted Therapy, 2022, 7, 57.	17.1	34
45	Genetic modulation of working memory deficits by ankyrin 3 gene in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 50, 110-115.	4.8	33
46	Analysis of Misdiagnosis of Bipolar Disorder in An Outpatient Setting. Shanghai Archives of Psychiatry, 2018, 30, 93-101.	0.7	33
47	Higher Plasma S100B Concentrations in Schizophrenia Patients and Dependently Associated with Inflammatory Markers. Scientific Reports, 2016, 6, 27584.	3.3	32
48	PLD3 in Alzheimer's Disease: a Modest Effect as Revealed by Updated Association and Expression Analyses. Molecular Neurobiology, 2016, 53, 4034-4045.	4.0	30
49	The Arc Gene Confers Genetic Susceptibility to Alzheimer's Disease in Han Chinese. Molecular Neurobiology, 2018, 55, 1217-1226.	4.0	30
50	The association between somatic symptoms and suicidal ideation in Chinese first-episode major depressive disorder. Journal of Affective Disorders, 2019, 245, 17-21.	4.1	30
51	Genetic association of the cytochrome c oxidase-related genes with Alzheimer's disease in Han Chinese. Neuropsychopharmacology, 2018, 43, 2264-2276.	5.4	29
52	Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype. Psychopharmacology, 2014, 231, 2211-2218.	3.1	28
53	Suicide risk in major affective disorder: Results from a national survey in China. Journal of Affective Disorders, 2014, 155, 174-179.	4.1	27
54	Influence of BCL2 gene in major depression susceptibility and antidepressant treatment outcome. Journal of Affective Disorders, 2014, 155, 288-294.	4.1	27

#	Article	IF	Citations
55	Integrative analyses of major histocompatibility complex loci in the genome-wide association studies of major depressive disorder. Neuropsychopharmacology, 2019, 44, 1552-1561.	5.4	27
56	Fatty acid amide hydrolase inhibitors produce rapid anti-anxiety responses through amygdala long-term depression in male rodents. Journal of Psychiatry and Neuroscience, 2017, 42, 230-241.	2.4	27
57	Perception of Stigma and Its Associated Factors Among Patients With Major Depressive Disorder: A Multicenter Survey From an Asian Population. Frontiers in Psychiatry, 2019, 10, 321.	2.6	26
58	Effects of tumor necrosis factor-α polymorphism on the brain structural changes of the patients with major depressive disorder. Translational Psychiatry, 2018, 8, 217.	4.8	25
59	<p>Cognitive symptoms in major depressive disorder: associations with clinical and functional outcomes in a 6-month, non-interventional, prospective study in China</p>. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 1723-1736.	2.2	25
60	The depression GWAS risk allele predicts smaller cerebellar gray matter volume and reduced SIRT1 mRNA expression in Chinese population. Translational Psychiatry, 2019, 9, 333.	4.8	25
61	COVID‐19 and post‐traumatic stress disorder: A vicious circle involving immunosuppression. CNS Neuroscience and Therapeutics, 2020, 26, 876-878.	3.9	25
62	Identification of SLC25A37 as a major depressive disorder risk gene. Journal of Psychiatric Research, 2016, 83, 168-175.	3.1	24
63	Increased ratio of high sensitivity C-reactive protein to interleukin-10 as a potential peripheral biomarker of schizophrenia and aggression. International Journal of Psychophysiology, 2017, 114, 9-15.	1.0	24
64	Rare Genetic Variants of the Transthyretin Gene Are Associated with Alzheimer's Disease in Han Chinese. Molecular Neurobiology, 2017, 54, 5192-5200.	4.0	24
65	Risk Factors for Anxiety in Major Depressive Disorder Patients. Clinical Psychopharmacology and Neuroscience, 2015, 13, 263-268.	2.0	24
66	Causes of drug discontinuation in patients with major depressive disorder in China. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 96, 109755.	4.8	23
67	Disrupted hemispheric connectivity specialization in patients with major depressive disorder: Evidence from the REST-meta-MDD Project. Journal of Affective Disorders, 2021, 284, 217-228.	4.1	23
68	Ifenprodil rapidly ameliorates depressive-like behaviors, activates mTOR signaling and modulates proinflammatory cytokines in the hippocampus of CUMS rats. Psychopharmacology, 2020, 237, 1421-1433.	3.1	22
69	Complement factor H and susceptibility to major depressive disorder in Han Chinese. British Journal of Psychiatry, 2016, 208, 446-452.	2.8	21
70	Neprilysin Confers Genetic Susceptibility to Alzheimer's Disease in Han Chinese. Molecular Neurobiology, 2016, 53, 4883-4892.	4.0	21
71	ZNF804A Genetic Variation Confers Risk to Bipolar Disorder. Molecular Neurobiology, 2016, 53, 2936-2943.	4.0	21
72	Reduced ENA78 levels as novel biomarker for major depressive disorder and venlafaxine efficiency: Result from a prospective longitudinal study. Psychoneuroendocrinology, 2017, 81, 113-121.	2.7	21

#	Article	IF	Citations
73	Duration of untreated bipolar disorder: a multicenter study. Scientific Reports, 2017, 7, 44811.	3.3	21
74	PTEN in prefrontal cortex is essential in regulating depression-like behaviors in mice. Translational Psychiatry, 2021, 11, 185.	4.8	21
75	Bilateral Habenula deep brain stimulation for treatment-resistant depression: clinical findings and electrophysiological features. Translational Psychiatry, 2022, 12, 52.	4.8	21
76	Association between brain-derived neurotrophic factor genetic polymorphism Val66Met and susceptibility to bipolar disorder: a meta-analysis. BMC Psychiatry, 2014, 14, 366.	2.6	20
77	Independent replications and integrative analyses confirm TRANK1 as a susceptibility gene for bipolar disorder. Neuropsychopharmacology, 2021, 46, 1103-1112.	5.4	20
78	Reduced nucleus accumbens functional connectivity in reward network and default mode network in patients with recurrent major depressive disorder. Translational Psychiatry, 2022, 12, .	4.8	20
79	The Relationship Between Neuroimmunity and Bipolar Disorder: Mechanism and Translational Application. Neuroscience Bulletin, 2019, 35, 595-607.	2.9	19
80	Functional Status of Hypothalamic–Pituitary–Thyroid and Hypothalamic–Pituitary–Adrenal Axes in Hospitalized Schizophrenics in Shanghai. Frontiers in Psychiatry, 2020, 11, 65.	2.6	19
81	The clinical correlates of comorbid anxiety symptoms and syndromal anxiety in patients with major depressive disorder. Psychiatry Research, 2018, 269, 251-257.	3.3	18
82	Risk Factors for Recent Suicide Attempts in Major Depressive Disorder Patients in China: Results From a National Study. Frontiers in Psychiatry, 2018, 9, 300.	2.6	18
83	Brain structural alterations in MDD patients with gastrointestinal symptoms: Evidence from the REST-meta-MDD project. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110386.	4.8	18
84	Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treat. Neuroscience Bulletin, 2015, 31, 572-588.	2.9	17
85	Common cellular and molecular mechanisms and interactions between microglial activation and aberrant neuroplasticity in depression. Neuropharmacology, 2020, 181, 108336.	4.1	17
86	Identification of a functional human-unique 351-bp Alu insertion polymorphism associated with major depressive disorder in the 1p31.1 GWAS risk loci. Neuropsychopharmacology, 2020, 45, 1196-1206.	5.4	17
87	Phenotypes, mechanisms and therapeutics: insights from bipolar disorder GWAS findings. Molecular Psychiatry, 2022, 27, 2927-2939.	7.9	17
88	Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments. Schizophrenia Research, 2014, 159, 376-384.	2.0	16
89	Identification of ANKK1 rs1800497 variant in schizophrenia: New data and meta-analysis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 564-571.	1.7	15
90	Preliminary Clinical Investigation of Combinatorial Pharmacogenomic Testing for the Optimized Treatment of Depression: A Randomized Single-Blind Study. Frontiers in Neuroscience, 2019, 13, 960.	2.8	15

#	Article	IF	Citations
91	Gastrointestinal Symptoms During Depressive Episodes in 3256 Patients with Major Depressive Disorders: Findings from the NSSD. Journal of Affective Disorders, 2021, 286, 27-32.	4.1	15
92	Evaluation of Mood Disorder Questionnaire (MDQ) in Patients with Mood Disorders: A Multicenter Trial across China. PLoS ONE, 2014, 9, e91895.	2.5	14
93	Efficacy and safety of escitalopram in treatment of severe depression in Chinese population. Metabolic Brain Disease, 2017, 32, 891-901.	2.9	14
94	Hypothalamic-Pituitary-End-Organ Axes: Hormone Function in Female Patients with Major Depressive Disorder. Neuroscience Bulletin, 2021, 37, 1176-1187.	2.9	14
95	Peripheral biomarkers to predict the diagnosis of bipolar disorder from major depressive disorder in adolescents. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 817-826.	3.2	14
96	Gender differences in quality of life and functional disability for depression outpatients with or without residual symptoms after acute phase treatment in China. Journal of Affective Disorders, 2017, 219, 141-148.	4.1	13
97	Abnormal white matter integrity in Chinese young adults with first-episode medication-free anxious depression: a possible neurological biomarker of subtype major depressive disorder. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2017-2026.	2.2	13
98	Clinical features of the patients with major depressive disorder co-occurring insomnia and hypersomnia symptoms: a report of NSSD study. Sleep Medicine, 2021, 81, 375-381.	1.6	13
99	The association of duration and severity of disease with executive function: Differences between drug-naïve patients with bipolar and unipolar depression. Journal of Affective Disorders, 2018, 238, 412-417.	4.1	12
100	Subtypes of treatment-resistant depression determined by a latent class analysis in a Chinese clinical population. Journal of Affective Disorders, 2019, 249, 82-89.	4.1	12
101	Altered resting-state fMRI signals and network topological properties of bipolar depression patients with anxiety symptoms. Journal of Affective Disorders, 2020, 277, 358-367.	4.1	12
102	Nerve growth factor variations in patients with mood disorders: no changes in eight weeks of clinical treatment. Neuropsychiatric Disease and Treatment, 2014, 10, 835.	2.2	11
103	Does early and late life depression differ in residual symptoms, functioning and quality of life among the first-episode major depressive patients. Asian Journal of Psychiatry, 2020, 47, 101843.	2.0	11
104	Guidelines Disconcordance in Acute Bipolar Depression: Data from the National Bipolar Mania Pathway Survey (BIPAS) in Mainland China. PLoS ONE, 2014, 9, e96096.	2.5	11
105	Evaluating the association between the SHANK3 gene and bipolar disorder. Psychiatry Research, 2016, 244, 284-288.	3.3	10
106	Differential gene expression in patients with subsyndromal symptomatic depression and major depressive disorder. PLoS ONE, 2017, 12, e0172692.	2.5	10
107	Disagreement and factors between symptom on self-report and clinician rating of major depressive disorder: A report of a national survey in China. Journal of Affective Disorders, 2019, 253, 141-146.	4.1	10
108	Weighted gene co-expression network analysis identifies specific modules and hub genes related to subsyndromal symptomatic depression. World Journal of Biological Psychiatry, 2020, 21, 102-110.	2.6	10

#	Article	IF	Citations
109	<p>Reliability and Validity of THINC-it in Evaluating Cognitive Function of Patients with Bipolar Depression</p>. Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2419-2428.	2.2	10
110	The relationship of olfactory function and clinical traits in major depressive disorder. Behavioural Brain Research, 2020, 386, 112594.	2.2	10
111	Association between residual symptoms and social functioning in patients with depression. Comprehensive Psychiatry, 2020, 98, 152164.	3.1	10
112	Employing biochemical biomarkers for building decision tree models to predict bipolar disorder from major depressive disorder. Journal of Affective Disorders, 2022, 308, 190-198.	4.1	10
113	Validation of the Chinese Version of the Short TEMPS-A and its application in patients with mood disorders. Journal of Affective Disorders, 2015, 170, 178-184.	4.1	9
114	Common variants at 2q11.2, 8q21.3, and 11q13.2 are associated with major mood disorders. Translational Psychiatry, 2017, 7, 1273.	4.8	9
115	Role of biological rhythm dysfunction in the development and management of bipolar disorders: a review. Annals of General Psychiatry, 2020, 33, e100127.	3.1	9
116	Probing the clinical and brain structural boundaries of bipolar and major depressive disorder. Translational Psychiatry, 2021, 11, 48.	4.8	9
117	Demographic and clinical differences between early- and late-onset major depressions in thirteen psychiatric institutions in China. Journal of Affective Disorders, 2015, 170, 266-269.	4.1	8
118	Demographic and clinical differences between early- and late-onset bipolar disorders in a multicenter study in China. Psychiatry Research, 2016, 246, 688-691.	3.3	8
119	Cortical thickness and subcortical volumes alterations in euthymic bipolar I patients treated with different mood stabilizers. Brain Imaging and Behavior, 2019, 13, 1255-1264.	2.1	8
120	Clinical characteristics associated with therapeutic nonadherence of the patients with major depressive disorder: A report on the National Survey on Symptomatology of Depression in China. CNS Neuroscience and Therapeutics, 2019, 25, 215-222.	3.9	8
121	Can seizure therapies and noninvasive brain stimulations prevent suicidality? A systematic review. Brain and Behavior, 2021, 11, e02144.	2.2	8
122	Impaired robust interhemispheric function integration of depressive brain from REST‐meta‐MDD database in China. Bipolar Disorders, 2022, 24, 400-411.	1.9	8
123	Early Diagnosis of Bipolar Disorder Coming Soon: Application of an Oxidative Stress Injury Biomarker (BIOS) Model. Neuroscience Bulletin, 2022, 38, 979-991.	2.9	8
124	Assessment and management of bipolar disorder: Principal summary of updated Chinese guidelines. Bipolar Disorders, 2018, 20, 289-292.	1.9	7
125	Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2473-2484.	2.2	7
126	Detection Study of Bipolar Depression Through the Application of a Model-Based Algorithm in Terms of Clinical Feature and Peripheral Biomarkers. Frontiers in Psychiatry, 2019, 10, 266.	2.6	7

#	Article	IF	Citations
127	Prevalence and clinical features of atypical depression among patients with major depressive disorder in China. Journal of Affective Disorders, 2019, 246, 285-289.	4.1	7
128	Symptomatology differences of major depression in psychiatric versus general hospitals: A machine learning approach. Journal of Affective Disorders, 2020, 260, 349-360.	4.1	7
129	The effect of thyroid function on the risk of psychiatric readmission after hospitalization for major depressive disorder. Psychiatry Research, 2021, 305, 114205.	3.3	7
130	No association between genetic variants of the LRRK2 gene and schizophrenia in Han Chinese. Neuroscience Letters, 2014, 566, 210-215.	2.1	6
131	Down-regulation of PRKCB1 expression in Han Chinese patients with subsyndromal symptomatic depression. Journal of Psychiatric Research, 2015, 69, 1-6.	3.1	6
132	Guidelines concordance of maintenance treatment in euthymic patients with bipolar disorder: Data from the national bipolar mania pathway survey (BIPAS) in mainland China. Journal of Affective Disorders, 2015, 182, 101-105.	4.1	6
133	Association analysis between mitogen-activated protein/extracellular signal-regulated kinase (MEK) gene polymorphisms and depressive disorder in the Han Chinese population. Journal of Affective Disorders, 2017, 222, 120-125.	4.1	6
134	Cognitive control and emotional response in attention-deficit/ hyperactivity disorder comorbidity with disruptive, impulse-control, and conduct disorders. BMC Psychiatry, 2021, 21, 232.	2.6	6
135	Blood‐based dynamic genomic signature for obsessive–compulsive disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 709-716.	1.7	5
136	Perspective on Etiology and Treatment of Bipolar Disorders in China: Clinical Implications and Future Directions. Neuroscience Bulletin, 2019, 35, 608-612.	2.9	5
137	Mental Health Service Challenges during the Early Stage of the COVID-19 Pandemic: Experience and Best Practices from China. Canadian Journal of Psychiatry, 2020, 66, 070674372097225.	1.9	5
138	Predictors and moderators of quality of life in patients with major depressive disorder: An AGTs-MDD study report. Journal of Psychiatric Research, 2021, 138, 96-102.	3.1	5
139	Exploring the Effects of Temperament on Gray Matter Volume of Frontal Cortex in Patients with Mood Disorders. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 183-193.	2.2	5
140	Atypical features and treatment choices in bipolar disorders: a result of the National Bipolar Mania Pathway Survey in China. Neuroscience Bulletin, 2015, 31, 22-30.	2.9	4
141	Evaluations of treatment efficacy of depression from perspective of both patients' symptoms and general sense of mental health and wellbeing: A large scale, multi-centered, longitudinal study in China. Psychiatry Research, 2016, 241, 55-60.	3.3	4
142	<p>Lack of Association Between PLA2G6 Genetic Variation and Parkinson's Disease: A Systematic Review</p>. Neuropsychiatric Disease and Treatment, 2020, Volume 16, 1755-1763.	2.2	4
143	Barriers and facilitators to implementing measurement-based care for depression in Shanghai, China: a situational analysis. BMC Psychiatry, 2021, 21, 430.	2.6	4
144	Advance in Diagnosis of Depressive Disorder. Advances in Experimental Medicine and Biology, 2019, 1180, 179-191.	1.6	4

#	Article	IF	Citations
145	Response Inhibition and Emotional Regulation in the Patients with Attention-Deficit/Hyperactivity Disorder and Comorbidity of Disruptive, Impulse-Control, and Conduct Disorders. Psychiatry Investigation, 2019, 16, 872-874.	1.6	4
146	Disturbances of affective cognition in mood disorders. Science China Life Sciences, 2021, 64, 938-941.	4.9	3
147	PAID study design on the role of PKC activation in immune/inflammation-related depression: a randomised placebo-controlled trial protocol. Annals of General Psychiatry, 2021, 34, e100440.	3.1	3
148	Difference in the regulation of biological rhythm symptoms of Major depressive disorder between escitalopram and mirtazapine. Journal of Affective Disorders, 2022, 296, 258-264.	4.1	3
149	Introduction. Advances in Experimental Medicine and Biology, 2019, 1180, 1-17.	1.6	3
150	Are subsyndromal symptomatic depression and major depressive disorder distinct disorders?. Shanghai Archives of Psychiatry, 2012, 24, 286-7.	0.7	3
151	Prevalence, clinical features and prescription patterns of psychotropic medications for patients with psychotic depression in China. Journal of Affective Disorders, 2022, 301, 248-252.	4.1	3
152	Biochemical and Endocrine Parameters for the Discrimination and Calibration of Bipolar Disorder or Major Depressive Disorder. Frontiers in Psychiatry, 0, 13, .	2.6	3
153	Editorial: Involvement of Neuro-Immune Mechanism and Brain–Gut Axis in Pathophysiology of Mood Disorders. Frontiers in Psychiatry, 2019, 10, 403.	2.6	2
154	Lower Health Literacy of Mania Than Depression Among Older People: A Random Survey of a Community Healthcare Service Center. Frontiers in Psychiatry, 2021, 12, 512689.	2.6	2
155	Gene expression signatures differentiating major depressive disorder from subsyndromal symptomatic depression. Aging, 2021, 13, 13124-13137.	3.1	2
156	Schizophrenia, bipolar disorder, or intracranial aneurysm? A case report. Brain and Behavior, 2021, 11, e2245.	2.2	2
157	Neural biomarker of functional disability in major depressive disorder: A structural neuroimaging study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110337.	4.8	2
158	A Breakthrough in Understanding the Rapid Antidepressant Effect of Ketamine Based on Structural Analysis. Neuroscience Bulletin, 2022, 38, 229-231.	2.9	2
159	Exploring the Core Genes of Schizophrenia Based on Bioinformatics Analysis. Genes, 2022, 13, 967.	2.4	2
160	Authors' reply. British Journal of Psychiatry, 2014, 205, 410-411.	2.8	1
161	Prescribing patterns of psychotropic medications and clinical features in patients with major depressive disorder with and without comorbid dysthymia in China. Asia-Pacific Psychiatry, 2017, 9, e12261.	2.2	1
162	The Developmental and Translational Study on Biomarkers and Clinical Characteristics-based Diagnostic and Therapeutic Identification of Major Depressive Disorder: Study Protocol for a Multicenter Randomized Controlled Trial in China . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2343-2351.	2.2	1

#	ARTICLE	IF	CITATIONS
163	Variants in the Upstream Region of the Insulin Receptor Substrate-1 Gene Is Associated with Major Depressive Disorder in the Han Chinese Population . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 501-507.	2.2	1
164	Comorbidity and Treatment in Older Psychiatric In-patientsâ€"A Retrospective Study in a Chinese Psychiatric Hospital. Frontiers in Psychiatry, 2021, 12, 722329.	2.6	1
165	Evaluating the efficacy and moderators of algorithm-guided antidepressant treatments of major depressive disorder. Journal of Affective Disorders, 2022, 297, 68-75.	4.1	1
166	Analysis of Seasonal Clinical Characteristics in Patients With Bipolar or Unipolar Depression. Frontiers in Psychiatry, 2022, 13, 847485.	2.6	1
167	Short- and Long-Term Influences of Benzodiazepine and Z-Drug Use in Patients with Bipolar Disorder Combined Sleep Disturbance during Affective Period: A Nine-Month Follow-Up Analysis. Disease Markers, 2022, 2022, 1-7.	1.3	1
168	Authors' reply. British Journal of Psychiatry, 2015, 206, 79-80.	2.8	0
169	A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 2441-2449.	2.2	0
170	Evaluation of antidepressant polypharmacy and other interventions for treatment-resistant depression. Shanghai Archives of Psychiatry, 2014, 26, 365-7.	0.7	0
171	A Preliminary Study of Different Treatment Strategies for Anxious Depression. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 11-18.	2.2	0